Quick Answer
Kymera Therapeutics, Inc. reported Stockholders Equity of $1.58 billion for fiscal year 2025.
Kymera Therapeutics, Inc. Stockholders Equity — Annual History
| Fiscal Year | Stockholders Equity | YoY Change |
|---|---|---|
| 2025 | $1.58B | +89.0% |
| 2024 | $835.62M | +111.6% |
| 2023 | $394.97M | -19.4% |
| 2022 | $490.15M | +6.6% |
| 2021 | $459.64M | +61.9% |
| 2020 | $283.89M | +481.5% |
| 2019 | -$74.41M | -116.1% |
| 2018 | -$34.44M | — |
Quarterly Stockholders Equity
| Quarter Ending | Stockholders Equity | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $946.26M | +6.0% | -2.6% |
| June 30, 2025 | $971.48M | +41.8% | +23.6% |
| March 31, 2025 | $786.23M | +10.5% | -5.9% |
| December 31, 2024 | $835.62M | +111.6% | -6.4% |
| September 30, 2024 | $892.93M | +125.8% | +30.4% |
| June 30, 2024 | $684.92M | +57.3% | -3.7% |
| March 31, 2024 | $711.20M | +53.9% | +80.1% |
| December 31, 2023 | $394.97M | -19.4% | -0.1% |
- Kymera Therapeutics, Inc. showed an increase of +89.0% in Stockholders Equity compared to the prior fiscal year.
- Over the 2018–2025 period, Kymera Therapeutics, Inc.’s stockholders equity has grown by 4687.2% (from -$34.44 million to $1.58 billion).
- The most recent figure is from Kymera Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: